NO20075603L - Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivater - Google Patents
Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivaterInfo
- Publication number
- NO20075603L NO20075603L NO20075603A NO20075603A NO20075603L NO 20075603 L NO20075603 L NO 20075603L NO 20075603 A NO20075603 A NO 20075603A NO 20075603 A NO20075603 A NO 20075603A NO 20075603 L NO20075603 L NO 20075603L
- Authority
- NO
- Norway
- Prior art keywords
- thiazole
- amino
- substituted
- disease
- pyrimidine derivatives
- Prior art date
Links
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 abstract 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000030613 peripheral artery disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000392 somatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Det er beskrevet nye 5-substituerte 7-amino-[1,3]tiazol[4,5-d]pyrimidinderivativer med formel (I) hvori R1, R2 , R3 , R4 og R5 er som definert i beskrivelsen, og farmasøytisk akseptable salter derav, sammen med fremgangsmåter for deres fremstilling, farmasøytiske sammensetninger som innbefatter dem og deres anvendelse ved behandling. Forbindelsene med formel (I) er CX3CR1 reseptorantagonister og er derved særlig anvendelige ved behandling eller profylakse av neurodegenerative forstyrrelser, demyelinerende sykdom, kardio- og cerebrovaskulære aterosklerotiske forstyrrelser, periferal arteriesykdom, reumatoid artritt, lungesykdommer slike som COPD, astma og smerte.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0500767 | 2005-04-06 | ||
| PCT/SE2006/000399 WO2006107258A1 (en) | 2005-04-06 | 2006-04-03 | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075603L true NO20075603L (no) | 2008-01-04 |
Family
ID=37073739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075603A NO20075603L (no) | 2005-04-06 | 2007-11-05 | Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivater |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7947693B2 (no) |
| EP (1) | EP1869056B1 (no) |
| JP (1) | JP5165553B2 (no) |
| KR (1) | KR101335055B1 (no) |
| CN (1) | CN101193897B (no) |
| AR (1) | AR055890A1 (no) |
| AT (1) | ATE487727T1 (no) |
| AU (1) | AU2006231836B2 (no) |
| BR (1) | BRPI0609738A2 (no) |
| CA (1) | CA2604017C (no) |
| CY (1) | CY1111316T1 (no) |
| DE (1) | DE602006018124D1 (no) |
| DK (1) | DK1869056T3 (no) |
| ES (1) | ES2354450T3 (no) |
| HR (1) | HRP20110047T1 (no) |
| IL (1) | IL185912A0 (no) |
| MX (1) | MX2007012060A (no) |
| NO (1) | NO20075603L (no) |
| NZ (1) | NZ561460A (no) |
| PL (1) | PL1869056T3 (no) |
| PT (1) | PT1869056E (no) |
| RS (1) | RS51581B (no) |
| RU (1) | RU2419623C2 (no) |
| SA (1) | SA06270072B1 (no) |
| SI (1) | SI1869056T1 (no) |
| TW (1) | TW200714605A (no) |
| UA (1) | UA90707C2 (no) |
| UY (1) | UY29454A1 (no) |
| WO (1) | WO2006107258A1 (no) |
| ZA (1) | ZA200708187B (no) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2641815T3 (es) | 2004-10-29 | 2017-11-14 | Eisai R&D Management Co., Ltd. | Tratamiento para enfermedades inflamatorias |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| RU2437889C2 (ru) * | 2006-09-29 | 2011-12-27 | Астразенека Аб | НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ |
| AU2009221063B2 (en) | 2008-03-07 | 2013-03-21 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1 |
| JP5509100B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用 |
| EA019711B1 (ru) | 2008-03-07 | 2014-05-30 | Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А. | ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40 |
| AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
| JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| JP6076913B2 (ja) | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | 癌からの転移を阻害する方法 |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| ES2642805T3 (es) | 2013-03-12 | 2017-11-20 | Eisai R&D Management Co., Ltd. | Sal de un derivado del ácido pirrolidín-3-ilacético y cristales de esta |
| BR112016006319A2 (pt) | 2013-09-27 | 2017-08-01 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
| WO2016200939A1 (en) * | 2015-06-08 | 2016-12-15 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
| US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
| GB201807898D0 (en) | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
| PE20251587A1 (es) | 2022-10-19 | 2025-06-16 | Astrazeneca Ab | 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1 |
| WO2025219939A1 (en) | 2024-04-17 | 2025-10-23 | Astrazeneca Ab | Salts and polymorphs of cx3cr1 modulators |
| WO2025219950A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Small molecule cx3cr1 modulators |
| WO2025219947A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Thio-substituted 1,3,5-triazine cx3cr1 modulators |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE543978A (no) | 1955-01-03 | |||
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| CA2031803C (en) | 1989-12-13 | 2001-05-29 | Ramakrishnan Nagarajan | Improvements in or relating to glycopeptide deriveratives |
| US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| EP0891978B1 (en) * | 1997-07-18 | 2002-03-20 | F. Hoffmann-La Roche Ag | 5H-Thiazolo (3,2-a) pyrimidine derivatives |
| WO1999051608A1 (en) | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| WO1999056760A1 (en) | 1998-05-01 | 1999-11-11 | Eli Lilly And Company | N1-modified glycopeptides |
| SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359081A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| DE60101372T2 (de) * | 2000-02-11 | 2004-10-14 | Astrazeneca Ab | Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
| SE0004110L (sv) | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
| SE0101082D0 (sv) | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| US8110209B2 (en) * | 2002-12-20 | 2012-02-07 | Xeris Pharmaceuticals Inc. | Intracutaneous injection |
| CA2541533A1 (en) * | 2003-10-07 | 2005-04-14 | Astrazeneca Ab | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| US20090239882A1 (en) * | 2004-12-17 | 2009-09-24 | Astrazeneca Ab | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
-
2006
- 2006-03-04 UA UAA200710491A patent/UA90707C2/ru unknown
- 2006-03-27 AR ARP060101169A patent/AR055890A1/es not_active Application Discontinuation
- 2006-03-28 TW TW095110726A patent/TW200714605A/zh unknown
- 2006-03-29 SA SA06270072A patent/SA06270072B1/ar unknown
- 2006-04-03 RS RS20110006A patent/RS51581B/sr unknown
- 2006-04-03 EP EP06717078A patent/EP1869056B1/en not_active Expired - Lifetime
- 2006-04-03 PT PT06717078T patent/PT1869056E/pt unknown
- 2006-04-03 NZ NZ561460A patent/NZ561460A/en not_active IP Right Cessation
- 2006-04-03 MX MX2007012060A patent/MX2007012060A/es active IP Right Grant
- 2006-04-03 SI SI200630886T patent/SI1869056T1/sl unknown
- 2006-04-03 AU AU2006231836A patent/AU2006231836B2/en not_active Ceased
- 2006-04-03 WO PCT/SE2006/000399 patent/WO2006107258A1/en not_active Ceased
- 2006-04-03 BR BRPI0609738-3A patent/BRPI0609738A2/pt not_active IP Right Cessation
- 2006-04-03 CA CA2604017A patent/CA2604017C/en not_active Expired - Fee Related
- 2006-04-03 CN CN2006800200726A patent/CN101193897B/zh not_active Expired - Lifetime
- 2006-04-03 HR HR20110047T patent/HRP20110047T1/hr unknown
- 2006-04-03 DE DE602006018124T patent/DE602006018124D1/de not_active Expired - Lifetime
- 2006-04-03 ES ES06717078T patent/ES2354450T3/es not_active Expired - Lifetime
- 2006-04-03 RU RU2007140551/04A patent/RU2419623C2/ru not_active IP Right Cessation
- 2006-04-03 PL PL06717078T patent/PL1869056T3/pl unknown
- 2006-04-03 JP JP2008505262A patent/JP5165553B2/ja not_active Expired - Lifetime
- 2006-04-03 DK DK06717078.7T patent/DK1869056T3/da active
- 2006-04-03 US US11/910,780 patent/US7947693B2/en active Active
- 2006-04-03 KR KR1020077022813A patent/KR101335055B1/ko not_active Expired - Fee Related
- 2006-04-03 AT AT06717078T patent/ATE487727T1/de active
- 2006-04-04 UY UY29454A patent/UY29454A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185912A patent/IL185912A0/en unknown
- 2007-09-25 ZA ZA200708187A patent/ZA200708187B/xx unknown
- 2007-11-05 NO NO20075603A patent/NO20075603L/no not_active Application Discontinuation
-
2010
- 2010-12-28 US US12/979,720 patent/US9440992B2/en active Active
-
2011
- 2011-01-13 CY CY20111100040T patent/CY1111316T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075603L (no) | Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivater | |
| NO20075610L (no) | Nye 5,7-disubstituerte [1,3]tiazol[4,5-d]pyrlmldin-2(3H)-onderivater | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| NO20091577L (no) | Nye 5,7-disubstituerte (1,3)tiazolo[4,5-D]pyrimidin-2(3H)-aminderivater og deres anvendelse i terapi | |
| PH12021552760A1 (en) | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 | |
| NO20071703L (no) | Kinazolinderivater | |
| WO2006067614A3 (en) | Heteroaromatic derivatives useful as anticancer agents | |
| SG162807A1 (en) | Azaindazole compounds and methods of use | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
| MY147390A (en) | Substituted isoindoles as bace inhibitors and their use | |
| SE0402735D0 (sv) | Novel compounds | |
| NO20092689L (no) | Quinuclidinolderivater som muskarin reseptorantagonister | |
| WO2009131974A8 (en) | Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use | |
| NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
| NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
| IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
| ATE531692T1 (de) | Als antagonisten am muskarinrezeptor geeignete guanidinhaltige verbindungen | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| NO20082054L (no) | Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser | |
| DK1926729T3 (da) | Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander | |
| WO2008104473A3 (en) | Pyrazolopyriidine derivatives and their use as kinase inhibitors | |
| NO20065327L (no) | Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid. | |
| TW200630366A (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |